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Abstract
Background: We have recently shown that the event-related potential biomarkers, mismatch negativity (MMN) and P3a, are
similarly impaired in young patients with schizophrenia- and affective-spectrum psychoses as well as those with bipolar
disorder. A data driven approach may help to further elucidate novel patterns of MMN/P3a amplitudes that characterise
distinct subgroups in patients with emerging psychiatric disorders.
Methods: Eighty seven outpatients (16 to 30 years) were assessed: 19 diagnosed with a depressive disorder; 26 with a
bipolar disorder; and 42 with a psychotic disorder. The MMN/P3a complex was elicited using a two-tone passive auditory
oddball paradigm with duration deviant tones. Hierarchical cluster analysis utilising frontal, central and temporal
neurophysiological variables was conducted.
Results: Three clusters were determined: the ‘globally impaired’ cluster (n = 53) displayed reduced frontal and temporal
MMN as well as reduced central P3a amplitudes; the ‘largest frontal MMN’ cluster (n = 17) were distinguished by increased
frontal MMN amplitudes and the ‘largest temporal MMN’ cluster (n = 17) was characterised by increases in temporal MMN
only. Notably, 55% of those in the globally impaired cluster were diagnosed with schizophrenia-spectrum disorder, whereas
the three patient subgroups were equally represented in the remaining two clusters. The three cluster-groups did not differ
in their current symptomatology; however, the globally impaired cluster was the most neuropsychologically impaired,
compared with controls.
Conclusions: These findings suggest that in emerging psychiatric disorders there are distinct MMN/P3a profiles of patient
subgroups independent of current symptomatology. Schizophrenia-spectrum patients tended to show the most global
impairments in this neurophysiological complex. Two other subgroups of patients were found to have neurophysiological
profiles suggestive of quite different neurobiological (and hence, treatment) implications.
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Introduction
A major topic of debate in psychiatric research is whether
categorical diagnoses (e.g. depressive disorder, bipolar disorder
and schizophrenia) represent distinct disorders (in terms of their
underlying neurobiology) or, if they are better represented as a
continuum of psychiatric illness [1–3]. Emerging neurobiological
evidence suggests that these separately categorised disorders share
more in common than previously purported [4–11] and that
endophenotypes are ideally placed to investigate the underlying
aetiology [8,12,13]. Moreover, this corpus of work suggests a
better understanding of these disorders may be achieved using a
‘bottom up’ approach utilising endophenotypes rather than
traditional ‘top down’ methods (based on symptomatology or
diagnoses). Data driven methods have the capacity to delineate
novel findings in cohorts of patients with emerging psychiatric
symptoms, given the potentially variable longitudinal trajectories
in such patients.
Over the past decade, impaired mismatch negativity (MMN)
and P3a, have been established as endophenotypes (or biomarkers)
of schizophrenia [14–17]. Both of these endophenotypes (but
MMN in particular) have been extensively studied in schizophre-
nia and have shown to be highly reliable over time, resilient to
practice effects, relatively independent of fluctuations in clinical
features, heritable, and when compared to controls, exhibit large
effect size deficits [8,13,14,18]. This research suggests that as
endophenotypes, MMN and P3a are robust and have utility in
probing the underlying neurobiology, and therefore clinical and
functional outcomes in complex diseases such as schizophrenia
and bipolar disorder. In deviance detection paradigms, these
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event-related potentials (ERPs) co-occur, are sequential [19] and
have been described as the ‘MMN/P3a complex’ [4,5,20–22].
MMN is thought to emerge from frontal and temporal brain
generators and it indexes the brain’s ability to extract relevant
information from an irrelevant background [23–26]. P3a is
generated fronto-centrally and reflects a subsequent reorienting
process [27]. There is an extensive literature showing associations
between MMN and cognition [4,21,28–31] as well as with
psychosocial functioning [5,21,22,28,32–35], whereby smaller
MMN amplitudes correspond with poorer levels of cognitive/
psychosocial functioning. Similar associations have been found
between P3a amplitudes and cognitive or psychosocial functioning
[21,22] suggesting that the MMN/P3a complex may be a marker
of the fundamental sensory processes that underlie higher-order
functions. Recently, studies have shown that these ERPs may not
be as specific to schizophrenia as initially considered. MMN is
thought to reflect NMDA receptor mediated neurotransmission
and therefore impaired MMN is likely to reflect glutamatergic
dysfunction [36,37], whereas variations in the amplitude of P3a
are thought to be primarily modulated by dopaminergic changes
[38,39]. Both of these neurotransmitters have been shown to be
dysregulated across several psychiatric disorders, making them
ideal for exploration in this cohort.
Our group has reported on the MMN/P3a complex in first-
episode psychosis, early psychosis subgroups (i.e. schizophrenia-
spectrum and affective-spectrum) and early bipolar-spectrum
disorders (with and without psychotic symptoms) [4,5,21]. We
have demonstrated that the MMN/P3a complex in early affective-
spectrum disorders is similarly impaired as in early schizophrenia-
spectrum disorders. Other studies have corroborated our findings
and have similarly reported impairments in the amplitudes of these
biomarkers in major depression and bipolar disorder [7,19,40–43].
There is now a confluence of evidence across a range of psychiatric
disorders reporting similar deficits in the MMN/P3a complex
suggesting that commonalities may exist in neuropathological
processes of early psychiatric illnesses.
In light of the aforementioned findings, a data driven approach
for investigating differences in MMN/P3a in a cohort of young
people with an admixture of psychiatric disorders may prove
insightful. Accordingly, we utilised cluster analysis, a hypothesis
generating and exploratory analysis, to determine unique neuro-
physiological profiles in young psychiatric patients and examined
whether these profiles could explain demographic, clinical and/or
cognitive differences. We hypothesised that distinct MMN/P3a
profiles would exist despite the clinical and cognitive features of
these patients.
Methods
The study and consent procedure was approved by the
University of Sydney Human Research Ethics Committee. All
participants were determined by their referring psychiatrist to have
the mental and intellectual capacity to give written informed
consent prior to participation in the study. All participants were
aged 16 years or older and were able to give their own written
informed consent (i.e. parental/guardian consent is not required
for those aged 16 and above according to the University of Sydney
Human Research Ethics Committee guidelines and Australian
law) prior to participation in the study.
Participants
Eighty-seven outpatients (16 to 30 years) with an admixture of
psychiatric disorders were recruited from specialised referral
services for the assessment and early intervention of mental health
problems [44,45]. Initial diagnoses were determined by a referring
psychiatrist, according to DSM-IV criteria [46]. Subsequently, a
research psychologist conducted a structured interview and case-
review (under the supervision of a psychiatrist or clinical
psychologist) utilising the psychosis and mood disorders section
of the Structured Clinical Interview for DSM-IV [47] to confirm
the diagnoses as follows: depressive disorders [major depressive
disorder (n = 12); major depressive disorder with psychotic features
(n = 7)]; bipolar disorders [bipolar I (n = 6); bipolar II (n = 6);
bipolar I with psychotic features (n = 10); bipolar II with psychotic
features (n = 4)]; psychotic disorders [schizophrenia (n = 24);
schizophreniform (n = 10); schizoaffective (n = 8)]. Patients were
tested under ‘treatment-as-usual’ conditions, and medication
regimens were not interrupted. Sixty-three patients were on an
antipsychotic, 34 were on an antidepressant, 20 were on a mood
stabiliser and 7 were on other psychotropic medication (i.e.
benzodiazepines or stimulants).
The healthy control group (n = 27; aged 16 to 30 years; 14
females) was recruited from the community in the same region and
were screened for psychopathology by a research psychologist via
clinical interview. Exclusion criteria for all participants were
diagnosis of a substance use disorder, medical instability, history of
neurological disease, medical illness known to impact brain
function, intellectual and/or developmental disability and insuffi-
cient English for assessment. In addition to this, control
participants with a family history of a psychotic- or bipolar-
disorder were excluded. All participants were asked to abstain
from illicit drug or alcohol use for 48 hours prior to testing. To
verify recent abstinence, participants also underwent an alcohol
breath test and a saliva drug screen to determine presence of
cannabinoids, meth/amphetamines, opiates, benzodiazepines and
cocaine. None of the participants were intoxicated at the time of
testing; if any of the participants failed the drug screening, their
assessment was cancelled and they were assessed on another day.
Clinical and Neuropsychological Assessment
To quantify current symptoms, a research psychologist made
clinical ratings using the Hamilton Depression Rating Scale
(HDRS, 17-item) [48] and the Brief Psychiatric Rating Scale
(BPRS) [49]. Positive and negative symptom sub-scores of the
BPRS were also calculated [50]. Participants were rated on the
social and occupational functioning assessment scale (SOFAS)
[51]. Premorbid intelligence (‘predicted IQ’) was estimated based
on performance on the Wechsler Test of Adult Reading [52].
Processing speed was assessed using the Trail-Making Test, part A
(TMT A) [53]; with set-shifting assessed by part B (TMT B).
Verbal learning and memory were assessed via the Rey Auditory
Verbal Learning Test (RAVLT); variables assessed were: imme-
diate recall (sum of trial 1–5; RAVLT A1 to A5) and 20-minute
delayed recall (trial 7; RAVLT A7). Patients were asked to
complete a self-report assessment which included the Kessler-10
(K-10) measuring psychological distress [54] and the Alcohol Use
Disorder Identification Test (AUDIT) to determine harmful levels
of alcohol use [55].
Neurophysiological Testing
After preparation for EEG recording, participants were
presented (via headphones) with 2,500 binaural pure tones
(1,000 Hz, 75 dBSPL, 10 ms rise/fall) at a 500 ms stimulus onset
asynchrony; this comprised a pseudo-random sequence of 2,300
(92%) 50 ms standard tones and 200 (8%) 100 ms deviant tones.
Tones were presented while participants watched a silent movie
and subjects were asked to report back the storyline of the movie at
the end of the task. A 64-channel Quik-Cap (Neuroscan) acquired
MMN/P3a Complex: Cluster Analysis
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EEG data from sites according to the standard 10–20 Interna-
tional system (including mastoids). Data was referenced to a nose
electrode. Vertical and horizontal electro-oculogram was moni-
tored for eye-blink artefacts and contaminated data was corrected
using established algorithms [56]. The mean amplitude, peak
amplitude and peak latency was determined for MMN and P3a,
according to established epoch windows of 135–205 ms and 250–
300 ms, respectively [4,5,18,21,22,29,32–34,42]. Scalp and EOG
potentials were digitised continuously at 500 Hz and signal
processing was performed offline using Neuroscan Scan 4.3.1
(Compumedics) software. Data were filtered using a bandpass filter
(0.15–20 Hz) and epochs of EEG that were contaminated by
movement artefacts (6100 mV) were rejected.
Statistical Analyses
Statistical analyses were performed using SPSS for Windows
20.0. To facilitate interpretation of ERP data in the cluster analysis
(see below), values for MMN amplitude at Fz were multiplied by
21.0 so that the changes in amplitudes were the same across the
three variables (i.e. MMN at Fz, MMN at M1 and P3a at Cz).
Following this, to achieve consistency within the cluster analysis all
three neurophysiological variables were converted to ‘standard-
ised’ values. A hierarchical cluster analyses utilising Wards method
of minimum variance with a squared Euclidean distance measure
was conducted to identify variation in patterns among neurophys-
iological variables. Typically, Fz and Cz as well as left and right
temporal sites (i.e. M1 and M2) have been examined in the same
studies. However, these pairs of variables are often highly
correlated, therefore, only one (from each ‘pair’) was chosen for
each component in order to circumvent any redundancy in the
cluster analysis. Firstly, a number of studies have reported that
patients have greater impairments in left, rather than right,
temporal MMN [5,57,58]. Secondly, imaging studies of psychosis
patients indicate greater reductions in left temporal volumes [59–
61]. For these reasons MMN at M1 (and not M2) was selected.
Finally, P3a at Cz was selected (rather than Fz) as this component
tends to be maximal at the vertex with increased sensitivity in
distinguishing patient groups [4,5,21].
Cluster analysis was based on previous similar studies [6,62–64]
and statistical recommendations [65]. Cluster analysis is a
classification technique for forming homogeneous groups within
complex data sets and the aim of the present study was to
determine whether a sample of young (16–30 yrs old), psychiatric
outpatients would form clusters on the basis of their neurophys-
iological profiles. A healthy control group was intentionally
omitted from the analysis as they are clearly different and to
include them in a cluster analysis would have led to an
unnecessary re-distribution of the results, in accordance with
established literature [6,63,66,67].
One-way between-subject analysis of variance (ANOVA) was
used to assess differences in the (uncorrected) neurophysiological
measures as well as in the demographic, clinical and neuropsy-
chological variables among cluster groups. The chi-square test was
used to compare the ratio of females to males across groups.
Significance levels were set at p,0.05. Levene’s test was used to
test for homogeneity of variance. Welch’s statistic was calculated,
with corrected df and p-values reported, where this assumption
was violated. For pair-wise cluster group comparisons post-hoc
Scheffe’s test were employed. A confirmatory discriminant
function analysis (DFA) was performed to determine which
neurophysiological variables best distinguished the cluster groups.
As a secondary analysis, separate ANOVAs were used to assess
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Agglomeration coefficients generated by cluster analysis re-
vealed a demarcation point between three- and four- cluster
solutions, suggesting that a three-cluster solution best distinguished
the cases; this was confirmed by inspection of the dendrogram.
The resultant clustering revealed three relatively well-sized groups
which were labelled according to their most distinguishing
characteristic; the first is the ‘globally impaired’ cluster (n = 53),
the second is the ‘largest frontal MMN’ (+FMMN) cluster (n = 17)
and the third is the ‘largest temporal MMN’ (+TMMN) cluster
(n = 17). Table 1 shows the cluster group mean amplitude (mV) and
standard deviations for each of the three (unstandardised)
neurophysiological variables. As revealed by ANOVA (see
Table 1), for each neurophysiological measure there was a
significant (p,.001) main effect of cluster group. Post-hoc
comparisons further revealed significant differences between
cluster pairs. The globally impaired and +FMMN clusters were
Table 2. Mean values (6 standard deviation) for demographic and clinical variables across the three cluster groups with






(N = 17) Significance Test [p]
Sex (f/m) 19/34 8/9 8/9 x2 (2) = 1.1 [.582]
Age, years 22.464.2 23.163.9 21.562.9 F (2, 35.8) = 0.8 [.358]
Age of onset 18.165.5 17.665.4 15.963.8 F (2, 76) = 1.1 [.355]
Predicted IQ 100.768.7 105.967.6 100.9612.2 F (2, 83) = 2.0 [.136]
SOFAS 60.1612.8 58.268.7 59.3610.8 F (2, 67) = 0.1 [.869]
HDRS total 9.266.8 11.069.6 11.467.9 F (2, 84) = 0.7 [.500]
BPRS total 38.3612.0 38.3612.2 45.0615.8 F (2, 83) = 1.8 [.169]
BPRS pos 11.364.8 11.364.3 14.565.5 F (2, 82) = 2.8 [.069]
BPRS neg 7.963.4 7.363.1 8.964.0 F (2, 82) = 0.9 [.421]
K 10 23.869.8 28.3610.4 24.769.8 F (2, 77) = 1.2 [.314]
AUDIT total 8.369.5 10.267.5 3.967.2 F (2, 86) = 2.4 [.096]
The Scheffe’s test was employed for post-hoc pair-wise comparisons between cluster groups, however, no significant differences were observed.
doi:10.1371/journal.pone.0051871.t002
Figure 1. Profile of standardised mean amplitude values (with standard error bars) for mismatch negativity (MMN) and P3a for the
‘globally impaired’ (red), ‘largest frontal MMN’ (blue) and ‘largest temporal MMN’ (green) cluster groups. Event-related potential mean
amplitudes (mV) were standardised and corrected (for consistency in polarity between variables) so that positive values reflect increased amplitudes.
doi:10.1371/journal.pone.0051871.g001
MMN/P3a Complex: Cluster Analysis
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e51871
differentiated by all three neurophysiological variables; that is,
frontal and left temporal MMN, and P3a amplitudes (p,.05), with
the globally impaired cluster showing reduced amplitudes across
each site. The globally impaired cluster was found to have
significantly reduced (p,.01) left temporal MMN and P3a
amplitudes compared with the +TMMN cluster. However, these
clusters showed similar impairments in frontal MMN amplitudes.
The +FMMN and +TMMN clusters were found to significantly
differ in frontal and temporal MMN (p,.001) but not P3a
amplitudes. As suggested by the overall pattern described above,
these clusters showed opposing amplitudes in frontal versus
temporal MMN (see Figure 1).
The neurophysiological profiles for the three cluster groups are
depicted in Figure 1. The globally impaired cluster showed
reductions in frontal MMN, temporal MMN and P3a amplitudes.
The +FMMN cluster was distinguished by having the largest
frontal MMN amplitudes with intermediate temporal MMN and
P3a. Finally, the +TMMN cluster was characterised by having the
most contrasting frontal as compared to temporal MMN
amplitudes. That is, the +TMMN cluster showed reductions in
frontal MMN but with corresponding increases in temporal MMN
amplitudes (relative to the remaining clusters). For P3a, the
+FMMN and +TMMN clusters showed very similar amplitudes.
As shown in Table 2, there were no significant main effects of
cluster group across demographic and clinical variables. Corre-
spondingly, the cluster-pair comparisons confirmed that there
were no significant differences in terms of distribution of gender,
age, age of psychiatric onset (that any psychiatric symptoms were
detected), predicted IQ and functional and clinical variables.
With regards to neuropsychological variables (see Table 3),
there were no significant main effects of cluster group or significant
cluster-pair comparisons for TMT A or TMT B. However, for
RAVLT SUM and RAVLT A7, there were significant (p,.01)
main effects of cluster group, with the only one significant pair-
wise comparison showing that the globally impaired cluster
performed worse that the +FMMN cluster in RAVLT A7.
Relationship between Cluster Membership and Primary
Diagnosis
The distribution of primary diagnoses among the cluster groups
are presented in Table 4. In terms of primary diagnoses, just over
half of the patients within the globally impaired cluster had a
psychotic disorder (55%) while patients with bipolar versus
depressive disorders were equally represented (25% vs. 21%,
respectively). Notably, all three psychiatric groups were more
equally distributed among the +FMMN and the +TMMN clusters
(see Table 4). The medication status of patients in each cluster is
summarised in Table 5. The prevalence of ‘any’ anti-psychotic,
anti-depressant, mood stabiliser or ‘other’ medication was
relatively balanced across the three cluster groups. Chi-square
tests revealed no significant differences in the presence (or not) of
each diagnostic or medication category among the three cluster
groups (all p..05).
Discriminant Function Analysis
With the three neurophysiological variables entered as predic-
tors, DFA confirmed the distinct profiling by generating two
functions to separate the 3 cluster-groups. The first function
accounted for 78.5% of the differences among the clusters [Wilk’s
l= 0.221, p,.001]. The second function explained the remaining
variance (21.5%) and was also statistically significant [Wilk’s
l= 0.652, p,.001]. As revealed by the structure matrix, the first
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(r = .523) whereas the second function had high discriminant
loadings for MMN at Fz (r = .873) and MMN at M1 (r = .729).
Comparison with Healthy Controls
As a secondary analysis, we sought to determine whether any of
the neurophysiological variables determined for each cluster group
were significantly abnormal compared to healthy controls. Chi-
square test confirmed that there was no difference in the ratio of
females-to-males between controls (14F: 13M) and the cluster
groups. Dunnett’s post hoc tests determined that there were no
significant differences between any of the cluster groups and
controls in terms of mean age (controls: 23.163.3 years).
However, despite each cluster group having a mean predicted
IQ score above 100, the control group had significantly higher IQ
scores compared to the globally impaired (p,.01) and the
+TMMN (p,.05) clusters.
As shown in Table 1 there was a range of significant pair-wise
(i.e. Dunnett’s) comparisons across the (uncorrected) neurophys-
iological variables. ANOVA confirmed that there were no
between-group differences in the number of epochs accepted for
each cluster group and the controls (p = 0.16). The globally
impaired cluster showed significant (p,.001) deficits in all three
neurophysiological variables as compared to controls, supporting
the global impairment finding described above. In contrast, the
+FMMN cluster did not differ significantly from controls. Finally,
the +TMMN cluster showed significant differences from controls
across MMN but not P3a variables; with reduced (at p,.001)
frontal MMN but increased (at p,.01) temporal MMN ampli-
tudes. Figure 2 illustrates the grand average MMN (frontal and
temporal) and P3a waveforms for each cluster group as compared
to controls.
There were differences between the cluster groups and controls
across all neuropsychological variables. Only the globally impaired
cluster exhibited reduced cognitive functioning across all mea-
sures. More specifically, the globally impaired cluster had
significantly poorer processing speed and set-shifting (both
p,.01) as well poorer verbal learning and memory (both
p,.001). Notably, the +TMMN cluster performed poorer than
controls in verbal learning and memory as well as processing speed
(all p,.05). There were no significant differences in the
neuropsychological measures between the +FMMN cluster and
controls.
Discussion
The results from our data indicate that three distinct
neurophysiological profiles are evident in our patient population.
The largest subgroup that was identified is characterised by a
global impairment of the MMN/P3a complex, as reflected by the
reductions in frontal and temporal MMN and P3a amplitudes.
The +TMMN cluster bears similarities to the globally impaired
cluster in terms of deficits in frontal MMN amplitudes, however
was unique from the other two clusters by exhibiting the largest
temporal MMN amplitudes. Finally, the +FMMN cluster was
distinguished from the other clusters in that it had the largest
frontal MMN amplitudes. Notably, no differences were observed
between all three cluster-groups for any clinical and cognitive
measures except that the globally impaired cluster displayed
poorer verbal memory compared to the +FMMN cluster.
Just over half (55%) of the patients in the globally impaired
cluster comprised of individuals with a primary diagnosis of a
psychotic disorder. Furthermore, the global impairments identified
in this cluster are consistent with the extant literature which
Table 4. Cross-tabulation of cluster by primary diagnosis.
Primary Diagnosis Globally impaired Largest frontal MMN Largest temporal MMN
Depression Count 11 5 3
% 21% 29% 18%
Bipolar Count 13 6 7
% 25% 35% 41%
Psychosis Count 29 6 7
% 55% 35% 41%
doi:10.1371/journal.pone.0051871.t004
Table 5. Cross-tabulation of cluster by medication category; Note: the ‘other psychotropic’ medications category includes
benzodiazepines or stimulants.
Current Medication Globally impaired Largest frontal MMN Largest temporal MMN
Anti-psychotic Count 41 11 11
% 77% 65% 65%
Anti-depressant Count 18 10 6
% 34% 59% 35%
Mood-stabiliser Count 12 5 3
% 23% 29% 18%
Other psychotropic Count 3 2 2
% 6% 12% 12%
doi:10.1371/journal.pone.0051871.t005
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reports that deficits in frontal and temporal MMN amplitudes are
well established findings in schizophrenia, and more recently,
earlier stages of psychotic disorders [4,5,15,21,23,31,43,57,58,68].
Moreover, it is well established that these neurophysiological
components reflect the integrity of the neural pathways that they
represent and as such, the relative health of these pathways can be
gleaned via measures such as amplitude as well as from the
corresponding morphology of these signals [12,36]. In the case of
the globally impaired cluster, the observed decrement in
amplitudes for both temporal (MMN) and frontal (MMN) signals
suggests that for these patients there may be a global disruption in
the MMN subsumed by deficits in both the sensory memory and
the automatic attention-switching mechanisms underlying devi-
ance detection [25,26,69]. Furthermore, this neurophysiological
profile corresponded with the worst overall cognitive profile; a
finding that is consistent with significant associations reported
between MMN and a range of cognitive variables [4,21,22,28–
31]. This association should be treated with caution as although
the globally impaired cluster was the only group to show
significant reduction across all neuropsychological measures
compared to controls, there was only one significant difference
among the cluster groups (see pair-wise comparisons in Table 3).
Potentially, such functional associations may be long-term, with
other evidence showing that patients with the greatest MMN
impairments at baseline had the worst functional outcomes at
follow-up [59].
These findings indicate that a subgroup of patients, at the early
stages of a psychotic disorder, already display significant neuro-
biological impairment. In other words, a global reduction in
MMN/P3a with corresponding impairments in cognitive perfor-
mance may be a biomarker for a more distinct and/or prolonged
psychotic (or related) illness. However, it is important to keep in
mind that 46% of the globally impaired cluster consists of
individuals with a primary affective disorder (i.e. a depressive or a
bipolar disorder with and without psychotic features). It is possible
that, especially given their younger age, that some of these patients
may be on a pathway to a psychotic illness (with the depressive
phenotype currently dominating). Notwithstanding, impaired
MMN and P3a has been documented in individuals with affective
disorders [4,5,7,9,43] and a recent study by our group has
reported impaired temporal MMN in an older sample of patients
with late-life depression indicating a specific disruption in temporal
networks [70]. Similarly, in psychotic disorders, significant
impairments in temporal MMN tend to be found in chronic
samples [57,58,68]. Critically, no studies have undertaken a data-
driven approach to investigate the extent to which there may be
subsets of patients with broad (in particular, temporal) impair-
ments in MMN so it is difficult to determine whether global
impairments in MMN/P3a represent severity, chronicity or both.
In all likelihood, the neurophysiological profile shown by the
globally impaired cluster may not be related to a particular
diagnosis or syndrome but rather represent more severe deficits
that are indicative of a developmental origin and related to general
brain dysfunction. As such, this may be a larger risk factor for
psychotic (and related) disorders, but not exclusively.
The +TMMN cluster bears similarities to the globally impaired
cluster in that they both show deficits in frontal MMN. Frontal
MMN impairments have been reported in both chronic schizo-
phrenia and also early stages of psychotic illnesses, such as first-
episode psychosis and ultra-high risk for psychosis [21,71–73]. On
the other hand, only one study has reported impairments in
temporal MMN at early stages of psychotic illnesses [5]; a finding
which is more common in chronic schizophrenia samples
[57,58,68]. We have proposed that deficits in temporal MMN
may develop with severity and/or chronicity [4,70]. In light of
this, the absence of impairment in temporal MMN in the
+TMMN cluster may indicate that individuals are less severe or
Figure 2. Grand average event-related potentials for the
‘globally impaired’ (red), ‘largest frontal MMN (blue)’, ‘largest
temporal MMN’ (green) cluster and control (black) groups at
(from top to bottom) frontal (Fz), central (Cz) and left temporal
(M1) sites. Note: M1 waveforms are reversed in polarity due to the
nose-referenced recording.
doi:10.1371/journal.pone.0051871.g002
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at an earlier stage of their illness compared to those in the globally
impaired cluster. The +TMMN cluster is equally represented by
individuals with psychotic (41%), bipolar (41%) and depressive
disorders (18%). Notably, Hafner and colleagues determined that
the most common and stable symptoms across affective and
psychotic disorders are depressive symptoms, negative symptoms
and functional decline [3]. This research suggests that at early
stages of both psychotic and affective disorders, the longitudinal
trajectory is often unclear. Therefore, we speculate that of the
individuals diagnosed with affective disorders in the +TMMN
cluster (who may not currently display positive symptoms of
psychosis), some might display such symptoms in the future and
show more widespread neurophysiological deficits indicating
further neurobiological changes.
The most surprising finding in this study was the significantly
increased frontal MMN which characterised the +FMMN cluster.
Increased frontal MMN is thought to reflect a hyper-glutamatergic
state such as that seen in those who are prone to alcoholism [74].
Of note, this cluster had the highest, albeit non-significant,
AUDIT total scores (see Table 2) suggesting some association with
risky drinking. These individuals may represent a distinctly
separate phenotype, despite symptomatology or diagnostic cate-
gory, and may have quite different treatment implications,
particularly given the recent interest in treating psychotic illnesses
with glutamatergic agents [75,76]. NMDA receptor hypo-function
and dopaminergic hyper-function are a widely accepted phenom-
enon of psychotic disorders [77,78]. These neurotransmitter
systems are closely linked since glutamate activates the inhibitory
systems of dopamine and this regulatory response is necessary to
maintain equilibrium of these neurotransmitters [79]. Antipsy-
chotics are primarily dopamine antagonists which reduce dopa-
mine levels but also increase glutamate levels [80]. Excessive
activity of NMDA receptors has been implicated in mood
disorders [81,82] and treatment with mood stabilisers (i.e. lithium
and lamotrigine) or antidepressants has been shown to reduce the
glutamate levels associated with such activity [83–85]. A better
understanding of the MMN profiles revealed in this study may
help to determine whether different types of glutamatergic agents
(if any) may be efficacious in treating certain individuals.
Although this is the first study using a data driven approach to
determine MMN/P3a complex profiles in young people with
psychiatric disorders, it is limited by its cross-sectional nature. For
future studies, data at multiple time points across illness trajectory
will help to better determine the temporal nature of illness.
Additionally, by better defining stage and severity of illness the
predictive capacity of these cluster profiles can be assessed. The
cohort in this study was a sample of convenience and overall there
are unequal ratios of primary psychotic, bipolar and depressive
disorders; future studies should ideally have larger sample sizes
with equal ratios of diagnostic category. Lastly, this analysis is
exploratory and further research is warranted to replicate these
findings.
This study highlights the utility of using a data driven method as
an alternative to categorising individuals with psychiatric illnesses.
In this respect, this study supports the notion that MMN and P3a
are well suited to probe the underlying neurobiology of psychiatric
disorders and provide important insights into the variations of
neurochemical functions that appear to exist despite diagnostic
category.
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